Gilead Buys Pipeline-In-A-Product With $21bn Immunomedics Deal

Acquisition Gives The Big Biotech Its First Approved Solid Tumor Drug

 
• By Mandy Jackson
  
two hands trying to connect couple puzzle piece with sunset background. Jigsaw alone wooden puzzle against sun rays. one part of whole. symbol of association and connection. business strategy.
Gilead's Immunomedics buy gives it a key piece in its oncology strategy – a late-stage solid tumor asset
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business